Medical Device Penetration Testing for Cardiovascular Devices
Penetration testing for pacemakers, ICDs, insertable cardiac monitors, and home-monitor backhaul. Pairing, telemetry, and field-update path testing.
Aligned to FDA's February 3, 2026 premarket cybersecurity guidance.
Cardiovascular devices - pacemakers, ICDs, CRT-Ds, insertable cardiac monitors, home-monitor transmitters - have the longest deployed lifetimes and the most public history of cybersecurity recalls in the industry. Our pen testing is built around the attack paths in published CISA advisories for cardiovascular devices: programmer-to-device pairing, RF telemetry confidentiality and integrity, home-monitor backhaul, and the long tail of postmarket update channels.
We exercise the in-clinic programmer interface (MedRadio RF on most current devices, BLE on newer patient-side links, inductive on older programmers and wake-up handshakes) for mutual authentication, session-key freshness, and replay resistance. We model the home-monitor as an untrusted bridge: assuming a compromised transmitter, can it issue programming commands or just relay telemetry? We check whether the device trusts any session that completes pairing. We also test the cellular and Wi-Fi backhaul out of the home monitor - TLS pinning, certificate validation, attestation of the monitor identity to the cloud - and the cloud-side APIs that clinicians use for remote follow-up. Implant-side, we evaluate the firmware update path: signed update enforcement, rollback protection, and behavior under interrupted update (because explant is not an option). The deliverable is a report your design team can act on AND a set of risk-control test evidence your regulatory team can drop into the SPDF and PMA cybersecurity sections.
Layers we exercise in this engagement
The cardiovascular system, from the outermost cloud and clinician surfaces down to the device itself. Highlighted layers are exercised by this medical device penetration testing services.
- 01Clinician portal Tested
- 02Cloud APIs Tested
- 03Cellular / Wi-Fi backhaul Tested
- 04Home monitor Tested
- 05RF / MICS / BLE telemetry Tested
- 06In-clinic programmer Tested
- 07Implant firmware Tested
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
Medical Device Penetration Testing Services engagement, end to end
Four phases, fixed fee, scoped to cardiovascular architecture from kickoff onward.
- 01
Scope + kickoff
Architecture review, attack-surface walkthrough, and threat-model alignment with your team. A written proposal within 24 hours.
- 02
Threat-model alignment
Every STRIDE entry in your threat model is matched to a planned test case so reviewers see one-to-one coverage.
- 03
Test execution
Device, cloud, mobile, BLE/RF, and OTA channels exercised in parallel by senior engineers - not a single web-app scan.
- 04
Submission-formatted report plus retest
eSTAR-format report with findings, CVSS 4.0 scores, remediation, and retests until every finding with uncontrolled risk is closed.
Findings we test for
Attack paths that can affect cardiovascular systems.
Programmer pairing can accept replayed handshakes
A captured pairing exchange can replay successfully against the same implant for the duration of its battery life. Mutual authentication can be present in the specification but absent from firmware.
Home monitor → implant can be trusted as an in-clinic programmer
Once paired, a home monitor can issue command opcodes that should be programmer-only. Firmware can fail to enforce the read-only role assumed in the threat model.
Cellular backhaul can lack certificate pinning
Home-monitor MQTT/HTTPS endpoints can validate the CA chain without pinning a specific certificate. A network-positioned attacker with a CA-trusted certificate can intercept telemetry and acknowledgments.
Cloud follow-up API can leak device identifiers across accounts
An insecure direct object reference on a device-episode endpoint can return another patient's ECG data to any authenticated account.
Legacy update tool can allow firmware downgrade
A field-service update tool from a previous generation can accept older signed bundles. An attacker with physical or programmer access can downgrade to a known-vulnerable build.
Public cardiovascular cybersecurity history
Recalls, CISA ICS-MA advisories, and disclosed research that shape what reviewers ask about in this segment - and what our scope is built to cover.
- CISA + FDA·2018
Medtronic CareLink 2090 programmer software-update vulnerability (ICSMA-18-058-01)
Software-update integrity gap allowed a network-positioned attacker to alter programmer software, indirectly affecting implant programming. FDA-issued safety communication followed.
Advisory - CISA + FDA·2017
Abbott (St. Jude) Merlin@home transmitter firmware update (ICSMA-17-009-01)
OTA firmware update issued to address authentication weaknesses on the home transmitter that could permit unauthorized programming commands to implants.
Advisory - CISA + FDA·2019
Medtronic Conexus telemetry protocol (ICSMA-19-080-01)
Conexus RF protocol lacked encryption and authentication, allowing nearby attackers to read or modify implant communications. Drove industry-wide expectations on telemetry confidentiality and integrity.
Advisory
"Blue Goat Cyber helped us navigate our first end-to-end cybersecurity testing for our wearable medical device. Their communication was excellent, their timeline exceeded expectations, and their report helped us achieve FDA clearance without any additional questions. It was a truly seamless experience."
Standard Medical Device Penetration Testing Services deliverables
The same deliverables the parent Medical Device Penetration Testing Services service ships with - tuned to your cardiovascular architecture.
- Device, firmware, and embedded testing: hardware teardown, JTAG/UART/SPI bus access, firmware extraction and reverse engineering, and exploitation of the secure boot, debug, and update paths. Done by operators who have tested infusion pumps, monitors, surgical robots, and implantables.
- Companion app and cloud API coverage: iOS/Android binary analysis, BLE pairing/GATT attacks, REST/MQTT/gRPC fuzzing, authentication and authorization testing, and tenant-isolation checks. We test the device as patients and clinicians actually use it, not in isolation.
- penetration test reports structured for FDA premarket submissions: executive summary, methodology, CVSS-scored findings tied to your threat model, reproduction steps, and documented tester independence, scope, methods, and results. Reviewer-ready, not a generic IT security PDF.
- Remediation guidance and re-test included: written fix recommendations per finding, engineer-to-engineer support during remediation, and unlimited retests until every finding with uncontrolled risk is closed, inside the fixed fee. Accepted residual risks remain documented in your risk file.
What lands in your eSTAR submission
Documents structured for the cybersecurity attachments of your submission - no reformatting on your side.
- Device, firmware, and embedded testing: hardware teardown, JTAG/UART/SPI bus access, firmware extraction and reverse engineering, and exploitation of the secure boot, debug, and update paths. Done by operators who have tested infusion pumps, monitors, surgical robots, and implantables.
- Companion app and cloud API coverage: iOS/Android binary analysis, BLE pairing/GATT attacks, REST/MQTT/gRPC fuzzing, authentication and authorization testing, and tenant-isolation checks. We test the device as patients and clinicians actually use it, not in isolation.
- penetration test reports structured for FDA premarket submissions: executive summary, methodology, CVSS-scored findings tied to your threat model, reproduction steps, and documented tester independence, scope, methods, and results. Reviewer-ready, not a generic IT security PDF.
- Remediation guidance and re-test included: written fix recommendations per finding, engineer-to-engineer support during remediation, and unlimited retests until every finding with uncontrolled risk is closed, inside the fixed fee. Accepted residual risks remain documented in your risk file.
Standards that apply
The Cardiovascular baseline, plus the call-outs that matter for medical device penetration testing services in this segment.
Segment-specific call-outs
ANSI/AAMI/IEC TIR60601-4-5
Reference it in your security risk-control evidence - particularly for programmer↔device interfaces.
FDA postmarket cybersecurity: Section 524B and FDA's postmarket cybersecurity guidance
Long-lived device fleets need SBOM monitoring + a documented coordinated vulnerability disclosure program. Pen test scope must include the postmarket update path, not just the as-shipped device.
What's not in scope
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
- Hospital enterprise IT network penetration testing
- Clinical efficacy or human-factors validation
- Physical security of manufacturing sites
- Source-code review (unless explicitly added as a separate engagement)
Medical Device Penetration Testing Services for Cardiovascular - FAQs
The questions buyers in this segment actually ask before scoping a medical device penetration testing services engagement.
Go deeper on Cardiovascular and premarket
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
The most common high- and critical-severity findings we surface in medical device penetration tests, what each one looks like in the field, and how to fix it before your FDA submission.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
Medical device cybersecurity should scale with device risk. Christian Espinosa argues why meeting only the Section 524B minimum leaves patients and submissions exposed.
VEX resources for medical device teams: a document guide, SBOM comparison, and common assessment mistakes, with evidence-based status and regulatory context.
Medical device cybersecurity for nanotech neurostimulation: a fictional STRIDE threat model linking controller risks, patient harms, controls, and testing.
Other engagements for Cardiovascular
Teams in this segment commonly bundle these alongside medical device penetration testing services.
Keep going
Scope a Medical Device Penetration Testing Services engagement for your cardiovascular program.
A 30-minute discovery call with Christian Espinosa, Founder and CEO, and Kristy Kennedy, VP of Sales.